Pierre Fabre and H-Immune partner on MAb cancer immunotherapies

French drugmaker Pierre Fabre and H-Immune have entered into a strategic research partnership which will utilize H-Immune’s unique technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics.

As a newly established bioscience company in the immuno-oncology field and spin out from the French Atomic Energy Commission, H-Immune has developed a proprietary in vitro immunization (IVI) technology leveraging a breakthrough approach to generate a series of fully human monoclonal antibodies (MAbs) against any therapeutic target, taking advantage of the affinity maturation processes performed in situ by B lymphocytes.

“Pierre Fabre is an ideal partner for H-Immune to help us begin to realize the full potential of our science and IVI technology which we plan to exploit through multiple industry partnerships,” said Luc Boblet, co-founder and chief executive of H-Immune, adding: “This collaboration is designed to catalyze and create tremendous ongoing scientific and product development synergy by leveraging each company’s strengths and assets.”